Discovery of Potent and Selective c-Met Degraders for Hepatocellular Carcinoma Treatment

作者：Wenjian Min, Huanaoyu Yang, Dawei Wang, Chunling Chen, Yanyin Wang, Yi Hou, Yasheng Zhu, Chengliang Sun, Xiao Wang, Kai Yuan, Peng Yang · 发表于：Journal of Medicinal Chemistry · 年份：2024 · DOI：10.1021/acs.jmedchem.4c01004 · 被引用次数：12 · 研究领域：Liver physiology and pathology、Drug Transport and Resistance Mechanisms、Cancer Mechanisms and Therapy

Targeting c-Met is a clinical trend for the precise treatment of HCC, but the potential issue of acquired drug resistance cannot be ignored. Targeted protein degradation technology has demonstrated promising prospects in disease treatment and overcoming drug resistance due to its special mechanism of action. In this study, we designed and synthesized two series of novel c-Met degraders and conducted a systematic biological evaluation of the optimal compound H11 . H11 exhibited good c-Met degradation activity and anti-HCC activity. Importantly, H11 also demonstrated more potent inhibitory activity against Ba/F3-TPR-MET-D1228N and Ba/F3-TPR-MET-Y1230H cell lines than did tepotinib. In summary, H11 displayed potent anti-HCC activity as a degrader and may overcome resistance to type Ib inhibitors, making it a new therapeutic strategy for HCC with MET alterations.